(Q33904314)

29 July 2017

1 reference

title

Review article: pharmacological treatment of the hepatorenal syndrome in cirrhotic patients (English)

1 reference

29 July 2017

0 references

1 reference

Dagher L

1

1 reference

29 July 2017

Patch D

2

1 reference

29 July 2017

Marley R

3

1 reference

29 July 2017

Moore K

4

1 reference

29 July 2017

Burroughs A

5

1 reference

29 July 2017

language of work or name

English

0 references

publication date

1 May 2000

1 reference

Alimentary Pharmacology & Therapeutics

29 July 2017

published in

1 reference

29 July 2017

volume

14

1 reference

29 July 2017

issue

5

1 reference

29 July 2017

page(s)

515-521

1 reference

Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club

29 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2000.00740.X

Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2000.00740.X

Peripheral arterial vasodilatation: determinant of functional spectrum of cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2000.00740.X

Renal prostaglandins and the control of renal function in liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2000.00740.X

Plasma endothelin immunoreactivity in liver disease and the hepatorenal syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2000.00740.X

Bacterial infection in the pathogenesis of variceal bleeding.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2000.00740.X

Pathogenesis and management of the hepatorenal syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2000.00740.X

Hepatorenal syndrome. New perspectives in pathogenesis and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2000.00740.X

Pathophysiology and treatment of ascites and the hepatorenal syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2000.00740.X

The effect of octapressin on renal and intrarenal blood flow in cirrhosis of the liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2000.00740.X

Hepatorenal syndrome and ascites--an introduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2000.00740.X

Enhancement of renal function with ornipressin in a patient with decompensated cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2000.00740.X

Renal and neurohormonal changes following simultaneous administration of systemic vasoconstrictors and dopamine or prostacyclin in cirrhotic patients with hepatorenal syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2000.00740.X

Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2000.00740.X

Octreotide in the treatment of the hepatorenal syndrome in cirrhotic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2000.00740.X

Combined use of dopamine and prostaglandin A1 in patients with acute renal failure and hepatorenal syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2000.00740.X

PROLONGED INFUSIONS OF ANGIOTENSIN II AND NOREPINEPHRINE AND BLOOD PRESSURE, ELECTROLYTE BALANCE, AND ALDOSTERONE AND CORTISOL SECRETION IN NORMAL MAN AND IN CIRRHOSIS WITH ASCITES.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2000.00740.X

Reversal of hepatorenal syndrome in four patients by peroral misoprostol (prostaglandin E1 analogue) and albumin administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2000.00740.X

Beneficial effects of the 2-day administration of terlipressin in patients with cirrhosis and hepatorenal syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2000.00740.X

10.1046/J.1365-2036.2000.00740.X

21 January 2018

Identifiers

DOI

1 reference

29 July 2017

1 reference